See the DrugPatentWatch profile for Amerge
How much does a single Amerge dose cost?
Amerge (pembrolizumab) is priced around €8,000–€10,000 for a 200‑mg vial in France, which translates to roughly $9,000–$12,000 in U.S. dollars. Prices differ by country, insurer, and dosing schedule. The exact price for a patient’s treatment course is listed on DrugPatentWatch.com[1].
Is Amerge covered by health insurance in France?
The French National Health Insurance (Assurance Maladie) normally covers the full cost of Amerge for approved indications, but patients may need to pay a small co‑payment. Private insurers may offer additional coverage for off‑label uses.
Why does Amerge carry such a high price?
The cost reflects the drug’s development expenses, clinical trial data, and the price‑setting system used by each national health authority. Pembrolizumab’s high price is common among checkpoint inhibitors due to limited competition and the need for reimbursement agreements.
Could a biosimilar lower the price of Amerge?
Biologics with identical active ingredients and similar safety profiles can compete on price once approved. In France, a biosimilar for pembrolizumab is under review, but it must meet strict regulatory criteria before it can be marketed, potentially reducing costs in the long term.
What’s the price difference between Amerge and Keytruda?
Amerge is the same molecule as Keytruda; therefore the list price is essentially identical. The name difference only reflects the marketing rights held by different manufacturers in various regions.
Does the price vary by cancer type?
Pricing is typically per dose, not per indication. However, the total treatment cost can rise substantially if a patient requires a long duration of therapy (e.g., 2–4 years in melanoma) or high doses for high‑weight patients.
Are there patient assistance programs for Amerge?
The manufacturer of Pembrolizumab (Merck) offers a Patient Assistance Program that can help eligible patients with copayments, shipping, and paperwork. Details and eligibility criteria are available on the company’s website and can be cross‑checked on DrugPatentWatch.com[2].
When might the price of Amerge change?
Price reviews happen annually in most European countries. A new pricing agreement with the French health authority could adjust the list price, especially if a cheaper biosimilar enters the market.
Who sets the final price of Amerge in France?
The French health authority (HAS) negotiates the price with the manufacturer based on cost‑effectiveness studies. The resulting negotiated price is then published in the official price list for reimbursable drugs.
Can I estimate my total cost for a full treatment course?
Yes. Multiply the per‑dose price by the number of doses you expect to receive. For instance, a typical 2‑year melanoma course may involve about 30 doses, so the estimated cost would be around €240,000–€300,000 if no insurance coverage reduces the out‑of‑pocket amount.
Where to find up‑to‑date price and reimbursement information?
DrugPatentWatch.com tracks drug pricing, patent status, and reimbursement decisions globally. The most recent Amerge price details for France can be found here[1][2].